Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06880744 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
A Phase 3 study of Ulcerative Colitis, sponsored by AbbVie.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 530
- Enrollment target
- 20
- Study locations
NCT06880744 is a Phase 3 study of Ulcerative Colitis that is actively recruiting participants, run by AbbVie. The registered enrollment target is 530 participants, below the 2,053-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (74% lower). The trial reports 20 study locations across 5 states.
The verdict
NCT06880744, a Phase 3 study of Ulcerative Colitis, is actively recruiting participants, sponsored by AbbVie.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 530 participants
- Enrollment target
- 20
- Study locations
Study Summary
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine).This study will evaluate how safe and effective risankizumab is compared to vedolizumab in treating adult participants with moderate to severe UC who are naive to targeted therapies (TaTs). Risankizumab and vedolizumab are approved medications for moderate to severe UC in multiple countries. Participants who meet the eligibility criteria will be randomized in a 1:1 ratio to receive open label risankizumab or vedolizumab. Approximately 530 adult participants with moderate to severe UC who are naïve to targeted therapies (TaTs) will be enrolled at 285 sites worldwide. For participants randomized to risankizumab, drug will be administered intravenous(IV) during the induction period followed by subcutaneous injection during the maintenance period. Participants randomized to vedolizumab will receive drug IV throughout the study. The duration of the study is approximately 69 weeks for participants randomized to risankizumab and 71 weeks for participants randomized to vedolizumab. This includes up to a 35-day screening period followed by a treatment period of 44 weeks for risankizumab and 46 weeks for vedolizumab. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular outpatient visits during the study. The effect and safety of the treatment will be checked by medical assessments, evaluation of side effects and completing questionnaires.
Conditions Studied
Interventions
- DRUG Vedolizumab
- DRUG Risankizumab
Study Locations (20)
Florida
- Novum Research /ID# 273587 - Clermont
- Hillcrest Medical Research /ID# 273593 - DeLand
- Florida Research Institute /ID# 275196 - Lakewood Rch
- Sanchez Clinical Research /ID# 273727 - Miami
- Medical Professional Clinical Research /ID# 275208 - Miami
- Sarkis Clinical Trials - Ocala /ID# 273595 - Ocala
- Endoscopic Research, Inc. /ID# 273548 - Orlando
- Digestive And Liver Center Of Florida - Orlando /ID# 276432 - Orlando
California
- UC San Diego Health System /ID# 273538 - La Jolla
- Gastro Care Institute /ID# 274873 - Lancaster
- UCLA Health - Digestive Health & Nutrition Clinic /ID# 274827 - Los Angeles
- Hoag Memorial Hospital Presbyterian /ID# 274364 - Newport Beach
- California Medical Research Associates /ID# 274787 - Northridge
- uc davis medical center - patient support services building /ID# 274251 - Sacramento
- Clinical Applications Laboratories - San Diego - 3rd Avenue /ID# 273527 - San Diego
Alabama
- Gastro Health Research - St. Vincent'S East /ID# 275089 - Birmingham
- Digestive Health Specialists /ID# 274785 - Dothan
- East View Medical Research /ID# 276222 - Mobile
Arizona
- Arizona Health Research /ID# 274366 - Chandler
Connecticut
- Danbury Hospital, Western Connecticut Health Network /ID# 275277 - Danbury
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 530 participants |
| Start Date | 2025-06-17 |
| Est. Completion | 2028-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06880744
The ClinicalTrials.gov registry entry for NCT06880744 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 530 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,053-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (74% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ulcerative Colitis appearing as the primary indexed condition, and to 2 interventions - of which Vedolizumab is the first listed.
NCT06880744 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Florida, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT06880744 about?
NCT06880744 is a clinical study titled "A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab". Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine).This study will evaluate how safe and effective risankizumab is compared to vedolizumab in treating adult participants with moderate to seve...
What is the current status of trial NCT06880744?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 530 participants. The study started on 2025-06-17. Estimated completion is 2028-09.
What conditions does trial NCT06880744 study?
This clinical trial studies the following conditions: Ulcerative Colitis.
What interventions are being tested in trial NCT06880744?
The interventions under investigation include: Vedolizumab (DRUG), Risankizumab (DRUG).
Who is sponsoring clinical trial NCT06880744?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06880744 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcerative Colitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 3
-
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
RECRUITING · Phase 3
-
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 3
-
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
RECRUITING · Phase 3
-
A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
RECRUITING · Phase 3
-
A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.